Gene expressed in prostate cancer
AssigneeAgensys, Inc.
InventorsDaniel E. H. Afar, Rene S. Hubert, Steve Chappell Mitchell
Life of this patent
Estimating the term…
Abstract
A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.
Claims5
A method of detecting the presence of a protein in a test sample, comprising:
- providing the test sample;
- contacting the test sample with a monoclonal antibody or antigen binding fragment thereof that binds the protein, which comprises the amino acid sequence of SEQ ID NO.2;
- and
- detecting the binding of the protein in the test sample thereto, wherein detection of the protein correlates to the presence of a prostate cancer cell in the test sample.
An in vitro method of delivering a detectable marker to a prostate cancer cell that expresses a protein comprising the amino acid sequence of SEQ ID NO:2, comprising:
- providing a monoclonal antibody or antigen binding thereof that binds specifically to the protein, wherein the antibody or antigen binding is labeled with the detectable marker;
- and
- contacting the cell with the antibody or antigen binding thereof such that the detectable marker is delivered.
Dependencies are inferred from the claim text.